P.A.W. Capital’s Akebia Therapeutics AKBA Stock Holding History

P.A.W. Capital’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-100,000	Closed	-$998K	–	67
2018 Q2	$998K	Buy	+100,000	New	+$1M	1.01%	31
2016 Q3	–	Sell	-40,000	Closed	-$299K	–	68
2016 Q2	$299K	Sell	40,000 -95,000	-70%	-$829K	0.34%	60
2016 Q1	$1.22M	Buy	135,000 +25,000	+23%	+$203K	1.36%	26
2015 Q4	$1.42M	Sell	110,000 -20,000	-15%	-$204K	1.61%	27
2015 Q3	$1.26M	Buy	+130,000	New	+$1.19M	1.44%	28

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

P.A.W. Capital's AKBA Position: Q3 2018 in Review

P.A.W. Capital sold out of Akebia Therapeutics (AKBA) in Q3 2018, closing a stake of 100,000 shares — an estimated $998K sold.

P.A.W. Capital first reported a position in AKBA in Q3 2015 and held it in 5 quarters. The position peaked at $1.42M in Q4 2015. 130 funds tracked by Wall St. Rank hold AKBA as of Q3 2018.

P.A.W. Capital reported no remaining Akebia Therapeutics position as of Q3 2018 after selling out during the quarter.
P.A.W. Capital sold 100,000 Akebia Therapeutics shares in Q3 2018, an estimated $998K.
P.A.W. Capital first reported a position in Akebia Therapeutics in Q3 2015 and held it in 5 quarters.
P.A.W. Capital's Akebia Therapeutics position peaked at $1.42M in Q4 2015.
130 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2018.

Based on P.A.W. Capital's 13F filing for Q3 2018, filed 24 Oct 2018.